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Abstract 
Specific changes in personality profiles may represent early non-cognitive symptoms of Alzheimer’s dis-
ease (AD). Evaluating the subject’s personality changes may add significant clinical information, as well 
as help to better understand the interaction between personality change, cognitive decline, and cerebral 
pathology. With this study we aimed to describe the relationship between personality changes and cere-
brospinal fluid (CSF) markers of AD pathology at early clinical stages of the disease. One hundred and ten 
subjects, of whom 66 cognitively impaired patients (57 with mild cognitive impairment (MCI), and 9 with 
mild dementia) and 44 healthy controls, had neuropsychological examination as well as lumbar puncture 
to determine concentrations of CSF biomarkers of AD pathology (amyloid beta1-42 (Aβ1-42), phosphory-
lated tau (ptau-181), and total-tau (tau)). The Revised NEO Personality Inventory (NEO-PI-R) was admin-
istered twice, once to evaluate subjects’ current personality and once to assess personality traits retro-
spectively 5 years before evaluation. Subjects with an AD CSF biomarker profile showed significant in-
crease in neuroticism and decrease in conscientiousness over time as compared to non-AD CSF bi-
omarker group. In regression analysis controlling for global cognition as measured by the MMSE score, 
increasing neuroticism and decreasing extraversion, openness to experience and conscientiousness were 
associated with lower Aβ1-42 concentrations but not with tau and ptau-181 concentrations. Our findings 
suggest that early and specific changes in personality are associated with cerebral AD pathology. Concen-
trations of CSF biomarkers, additionally to severity of the cognitive impairment, significantly contribute 
in predicting specific personality changes. 
Keywords: Personality changes; cerebrospinal fluid biomarkers; Revised NEO Personality Inventory 
(NEO-PI-R); Alzheimer’s disease (AD); mild cognitive impairment (MCI)  
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1. Introduction
With the rising number of elderly people suffering from Alzheimer’s disease (AD), it is of high clinical 
importance to investigate and address its early clinical changes. Patients with mild cognitive impairment 
(MCI) are characterized by a noticeable decline in cognitive abilities, which is relatively greater than 
normal age-related change observed in healthy population, and have increased risk of developing AD 
dementia during the following year (Petersen et al., 1999; Winblad et al., 2004). 
Neuropathological changes, in particular the cerebral accumulation of amyloid pathology, tau hyper-
phosphorylation, and neuronal injury precede the first symptoms of dementia by years (Jack Jr et al., 
2013; Jansen et al., 2015) and are paralleled by  decreasing concentrations of amyloid beta 1-42 (Aβ1-42 ), 
and increasing of tau phosphorylated at threonine 181 (ptau-181) and total tau (tau) in the cerebrospinal 
fluid (CSF), respectively,  at the pre-symptomatic and the MCI stages ). The presence of both amyloid and 
tau pathology is required to consider an individual as having AD pathology and the ratios of CSF tau/Aβ1-
42 and ptau/Aβ1-42  (or Aβ1-42 /tau and Aβ1-42/ptau) have been shown to outperform single markers in iden-
tifying subjects with dementia due to AD and predicting cognitive decline in subjects with MCI (Duits et 
al., 2014). 
Cognitive decline and progress to dementia is accompanied by personality changes that occur alongside 
and sometimes manifest before the cognitive symptoms (Balsis et al., 2005; von Gunten et al., 2009). 
Personality traits represent individual tendencies to think, feel and behave in certain ways that affect the 
individual’s interactions with external world (Krueger et al., 2000). The five-factor model (Goldberg, 
1990) (Costa Jr and McCrae, 1990) is a widely used model describing human personality along the di-
mensions of neuroticism, extraversion, openness to experiences, agreeableness, and conscientiousness. 
Studies report that these personality traits remain stable across the life span (Costa Jr and McCrae, 1992; 
Costa et al., 2000), but can be modified in relation to brain changes resulting from neurological diseases 
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(Duberstein et al., 2011; Terracciano et al., 2005; Wang et al., 2009). A systematic review on personality 
changes in AD dementia found increase in neuroticism, and decrease in extraversion, openness, agreea-
bleness and conscientiousness (Robins Wahlin and Byrne, 2011). Recently, changes in conscientiousness 
and neuroticism were found in clinically diagnosed AD dementia (Pocnet et al., 2013). Similar results 
were reported in subjects with MCI compared to controls: MCI subjects showed decreased conscien-
tiousness and extraversion and increased neuroticism (Donati et al., 2013). However, patients with MCI 
represent a heterogeneous group regarding the aetiology of cognitive impairment and only a part of 
them may have cerebral AD pathology and develop AD dementia over time. None of the previous studies 
included clinical follow-up or biomarkers of disease pathology to confirm the diagnosis of AD, and to 
address the question whether the observed personality changes are due to cognitive impairment of dif-
ferent aetiologies or may be more specifically related to AD pathology. Information about changes in 
personality is accessible through questionnaires completed by patients relatives, and do not involve any 
invasive techniques. Evaluating the subject’s personality changes may add significant clinical information 
(Balsis et al., 2005), as well as help to better understand the interaction between personality change, 
cognitive decline, and cerebral pathology. With this study we aim to explore the relations between 
changes in personality and CSF biomarkers of AD pathology. 
2. Material and Method
2.1 Sample 
One hundred and ten community dwelling participants were included in this study, of whom 44 were 
cognitively healthy volunteers and 66 had mild cognitive impairment (MCI, N=57) or mild dementia 
(N=9). The participants with cognitive impairment were recruited among patients attending the Memory 
clinics of the Department of psychiatry and the Department of clinical neurosciences at the Lausanne 
University Hospital. The patients had no major psychiatric or neurological disorders, nor substance abuse 
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or severe or unstable physical illness that explained cognitive impairment. Healthy subjects were recruit-
ed in the community through journal announcements and word of mouth. All participants had a com-
prehensive medical, psychiatric, neuropsychological and psychosocial evaluation, as well as brain MRI or 
CT scans and venous and lumbar puncture. The MRI and CT scans were used in order to exclude patients 
with cerebral pathologies possibly interfering with cognitive performance, including relevant vascular 
damages. 
2.2 Procedure 
The study was approved by the Ethics Committee of the Faculty of Biology and Medicine of the Universi-
ty of Lausanne. The aims of the research project were clearly explained to all participants and the in-
formed written consent to participate in the study was administered and signed by all. Clinical data from 
a part of the participants (N=41) was also considered in two previous publications  (Pocnet et al., 2013) 
(Donati et al., 2013). 
Diagnosis of MCI or mild dementia was based on neuropsychological and clinical evaluation and was 
made at a consensus conference of psychiatrists, neuropsychologists, and/or neurologists prior to inclu-
sion into the study. MCI was diagnosed according to widely used consensus recommendations (Winblad 
et al., 2004).  The participants in this group had memory impairment (<–1.5 standard deviation (SD) be-
low the means adjusted for gender, age and education in the verbal memory task of Buschke Double 
Memory Test (Buschke et al., 1997)) and/or impairment in another cognitive domain, and a Clinical De-
mentia Rating Scale (CDR)  (Morris, 1993) score of 0.5. The diagnosis of probable AD dementia was based 
on the clinical diagnostic criteria for probable dementia due to AD according to recommendations from 
the National Institute on Aging and Alzheimer’s Association (McKhann et al., 2011) and DSM-IV criteria 
for dementia of the Alzheimer type (American-Psychiatric-Association, 1994). Participants in this group 
had a CDR score of 1. The control subjects had no history or evidence of cognitive impairment, and their 
CDR score was 0. 
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The CDR is a semi-structured, clinician-rated interview with the patient and an appropriate informant, 
widely used to assess the progression of dementia. It is based on the ratings of the patient’s cognitive 
and functional impairment in 6 domains:  memory, orientation, judgment and problem solving, commu-
nity affairs, home and hobbies, and personal care (Morris, 1993). Scores in each of area range from 0 to 
3, representing “none” to “severe” impairment. CDR has a very high interrater reliability (Rockwood et 
al., 2000) and thus appears to be a reliable and valid measurement for assessing cognitive performance 
stages in dementia. 
2.3 CSF biomarkers and APOE genotyping 
Venous and lumbar punctures were performed between 8:30 and 9:30 am after overnight fasting at the 
recruiting Memory centres. CSF was collected by lumbar puncture, using a standardized technique with a 
22G “atraumatical” spinal needle while the patient was sitting or lying (Popp et al., 2007). Ten to twelve 
ml of CSF were obtained using polypropylene tubes. Routine cell count and protein quantification were 
performed. Remaining CSF was frozen in aliquots and stored at -80 °C until assay. We measured Aβ1-42, 
tau, and ptau-181 concentrations with ELISA kits, using commercially available assays (Fujirebio, Gent, 
Belgium). A pathological CSF AD biomarker profile was defined as a ptau-181/Aβ1-42 ratio >0.078, based 
on previous analysis of center data and published recommendations (Duits et al., 2014; Molinuevo et al., 
2014). The centre cut-off was determined in a previous unpublished study using data from 120 subjects 
(48 healthy volunteers with normal cognition and 72 memory clinic patients with MCI or mild dementia 
of AD type) as the value that optimized the Youden index of the Received Operating Characteristic (ROC) 
curve of prediction for CDR categories (CDR = 0 vs. CDR > 0). The cut-off was further shown to be a highly 
significant predictor of cognitive decline after controlling for multiple possible confounders (unpublished 
data). 
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Carrying the APOEε4 allele is the strongest known genetic risk factor for sporadic AD. It may influence
the relationships between AD pathology, personality and clinical manifestations (Dar-Nimrod et al., 
2012), and accelerate the generation of amyloid pathology at very early disease stages (Jansen et al., 
2015; Popp et al., 2010). Accordingly, the APOE genotype was determined and considered to evaluate 
possible interactions and effects on the addressed relationships. Leukocyte genomic DNA was isolated 
from EDTA blood with the Qiagen blood isolation kit (Qiagen, Hilden, Germany) and the APOE genotype 
was determined on the LightCycler (Roche Diagnostics, Basel, Switzerland). 
2.4 Neuropsychological and functional assessment 
Neuropsychological tests were used to assess cognitive performance in the domains of memory (sponta-
neous and cued-recall 48-item task (Van der Linden and Adam, 2004), executive function (a verbal fluen-
cy task (categorical and literal fluency in 2 min), a flexibility task - the Trail Making Test A and B (Reitan, 
1958), and an inhibition task - the Stroop test (Bayard et al., 2009), and visuospatial functions (CERAD 
copy image test). The MMSE (Folstein et al., 1975) was used to assess participants’ cognitive level. De-
pression and anxiety were assessed using the Hospital Anxiety and Depression scale (HAD) (Zigmond and 
Snaith, 1983). Cognitive complaints questionnaire (Questionnaire de Plainte Cognitive, QPC, (Thomas-
Antérion et al., 2004; Thomas-anterion et al., 2004)) was employed to evaluate participants’ memory 
failures and cognitive complaints. 
Psychosocial and functional assessment included the ADL (Katz, 1997) and instrumental ADL (Lawton and 
Brody, 1970), the NPIQ (Cummings et al., 1994), and the IQCODE (Jorm and Jacomb, 1989) question-
naires, completed by the family members of the participants. All tests and scales are validated and wide-
ly used in the field. 
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2.5 Personality assessment 
Patients’ proxies were asked to complete the NEO Personality Inventory Revised (NEO-PIR, Form R (Costa 
and MacCrae, 1992)), which is based on the FFM (Costa Jr and McCrae, 1990). This dimensional personal-
ity model derived from factor analyses performed on a large number of self- and peer reports on per-
sonality-relevant adjectives and questionnaire items (Costa Jr and McCrae, 1990), that revealed five di-
mensions describing personality, i.e. neuroticism, extraversion, openness to experience, agreeableness, 
and conscientiousness. Each of these dimensions is composed of six subcomponents or facets (see Table 
A in Annexes for description of the domain and facet scales). The NEO-PI-R is a questionnaire composed 
of 240 items and used for peer ratings which has well-established reliability and validity data in older 
populations (McCrae and Costa, 1987). In our study, each informant completed the NEO-PI-R twice, once 
to describe the patient as he/she was 5 years prior to the inclusion, and once to describe the participant 
at the time of the study. 
2.6 Statistical analyses 
The data was analysed using SPSS, version 20, and R (R Development Core Team, 2009). To characterize 
and compare the cognitively impaired (CI, including patients with MCI and mild dementia) and control 
groups we applied descriptive statistics (Cohen, 2013), Mann-Whitney test (Field, 2013) and chi-square 
test for non-normally distributed data and Student’s t-test for independent samples. Comparison of per-
sonality changes between subjects who have non pathological CSF biomarker levels (non-AD CSF group) 
and those who have pathological CSF  biomarker levels (AD CSF group) was performed using Welch’s t-
test (Welch, 1938) and also Mann-Whitney test. The change in personality was computed by subtracting 
the retrospective from the current scores. To screen for relations between personality changes and cer-
ebral pathology we counted correlations for the change in each NEO-PI-R domain and each biomarker. 
Further, series of linear regressions were conducted for the CI and control groups combined to deter-
mine whether CSF biomarker concentrations predict changes in personality. We included MMSE score 
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and CSF biomarker level in our model as predictors and change in each personality domain separately as 
dependent variable. In order to control for influential observations in our data we further performed the 
robust regression on the same variables. To assign the measures of accuracy we applied ordinary non-
parametric bootstrapping. We then performed series of regressions where we included the change in 
each personality domain as dependent variable and age, gender, MMSE score, and concentrations of CSF 
biomarkers as predictors. 
3. Results
Descriptive statistics of the sample are shown in Table 1. The CI and control groups differed significantly 
in age and APOEε4 status. There were significantly more females than males in the control group, alt-
hough gender distribution in the CI group was equal. The mean MMSE score was relatively high in the 
subjects with CI (26.0 points) suggesting a very mild impairment in global cognitive performance in this 
group. The HAD depression and anxiety scores were similar in both groups. Furthermore, participants in 
CI group scored significantly higher than controls on QPC and IQ-code questionnaires. 
3.1 Personality change and CSF biomarker concentrations among CI and control groups 
The concentration of CSF biomarkers was significantly different in two groups (see Table 1). The concen-
trations of tau, ptau-181, and the tau/Aβ1-42 and ptau-181/Aβ1-42 ratios were significantly higher in the CI 
group than in healthy controls, while Aβ1-42 level was lower in the CI group compared to controls. 
The personality changes in the CI group were markedly different from those in the control group. The 
mean personality change score was increased in neuroticism, decreased in extraversion, agreeableness, 
and conscientiousness for the CI group compared to the healthy controls (table 2). Effect sizes were larg-
er for neuroticism and conscientiousness than for the other traits. Concerning retrospective personality 
scores, openness to experience was significantly lower in CI group compared to controls. Current per-
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sonality scores between the two groups differed in domains of extraversion, openness to experience and 
conscientiousness (see table 2). 
3.2 Personality changes and CSF biomarkers 
Subjects with an AD biomarker profile had lower anxiety and MMSE score, but did not differ in depres-
sion score (see table 3). Mann-Whitney test performed on changes in personality domains score re-
vealed significant increase in neuroticism and decrease in conscientiousness in the AD CSF group com-
pared to non-AD CSF group (see table 3, figure 1). 
We further performed a correlation analysis which revealed robust relationships between changes in 
personality domains and cerebral pathology as measured by the CSF biomarkers (see table 5). 
Multiple linear regression models, including MMSE score, Aβ1-42 concentrations, tau concentrations as 
predictors and change in each personality dimension separately as dependent variables, revealed that 
increase in domain of neuroticism was predicted by lower MMSE score (β = -0.822, p < .05) and lower 
Aβ1-42 concentrations (β = -0.011, p < .05). The decrease in extraversion was only predicted by lower Aβ1-
42 concentrations (β = 0.01, p < .01), and not by MMSE score (β = 0.577, p = 0.09). Both lower MMSE 
score and lower levels of Aβ1-42 contributed significantly to decrease in conscientiousness (β = 2.375, p < 
.001; β = 0.012, p < .05 respectively). Decrease in agreeableness was predicted by lower MMSE score (β = 
0.047, p < .05), and not by Aβ1-42 concentrations (β = -0.0002, p = 0.9). The concentrations of tau did not 
reach significant level in predicting changes in any of the personality domains. Those results were con-
firmed by robust linear regression model (see table 4a) and by bootstrapping procedure. 
Similar results were obtained when including ptau concentrations instead of tau concentrations as pre-
dictor (see table 4b for model estimates). Additionally to the results described previously, in the model 
with ptau levels, the decrease in openness to experience was associated to lower Aβ1-42 levels (β = 0.004, 
p < .05), although this association was not confirmed by robust regression. The ptau levels did not con-
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tribute in explaining any of personality domains. Robust linear regression and bootstrapping procedure 
confirmed those results. 
In the regression analysis including age, gender, MMSE score, Aβ1-42,  tau, or ptau) concentrations the 
Aβ1-42 concentrations were positively associated with changes in neuroticism (F=5.481, p<0.001; β=-
0.234, p=0.024) , extraversion (F=5.195, p=0.001; β=0.307, p=0.003),openness to experience (F=2.935, 
p=0.024; β=0.238, p=0.027), and conscientiousness (F=12.386, p<0.001; β=0.206, p=0.028). The tau and 
ptau levels did not contribute in predicting personality changes. 
4. Discussion
In this study we found that biomarkers of AD pathology are associated with specific changes in personali-
ty domains. Subjects with pathological CSF biomarker levels show increase in neuroticism and decrease 
in conscientiousness as compared to subjects with normal CSF biomarker levels. Furthermore, lower 
Aβ1-42 concentrations independently contribute in predicting increasing levels of neuroticism, and de-
creasing levels of extraversion and conscientiousness when controlling for global cognitive performance. 
When comparing CI and control groups we found that in CI subjects neuroticism increased, while extra-
version, conscientiousness and agreeableness decreased over the 5 years period prior to the cognitive 
assessment. These findings are in line with studies that investigated the association between changes in 
personality and cognitive impairment and dementia in the elderly. Personality changes towards higher 
neuroticism and lower extraversion, conscientiousness and openness to experience have been observed 
in memory-impaired subjects (Siegler et al. (1991). Patients with clinically diagnosed AD dementia have 
been shown to undergo significant personality changes as reported by the patients’ caregivers, the most 
consistently reported being decreases in conscientiousness and extroversion, and increase in neuroti-
cism (Chatterjee et al., 1992; Pocnet et al., 2013). Likewise, changes in the same personality domains 
were observed in subjects with MCI (Donati et al., 2013). Together, these findings suggest a predictable 
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direction of personality changes in subjects with MCI and dementia. Results coming from our study con-
firm this pattern of changes. 
The evolution of personality over the life span has been explored by several longitudinal studies and 
personality was shown to keep a certain stability in adulthood and throughout normal ageing (Haan et 
al., 1986; McCrae and Costa, 1987) except for slight possible changes including a decrease in extraver-
sion and an increase in agreeableness (Field and Millsap, 1991). In dementia, changes in agreeableness 
may follow the opposite direction when compared to normal ageing while changes in extraversion follow 
the same direction (Robins Wahlin and Byrne, 2011). Our study not only shows that there is a distinctive 
pattern of personality changes in subjects with cognitive impairment, but it also reveals that this pattern 
is specific and is associated with concentrations of CSF markers reflecting AD pathology. Intriguingly, we 
observed associations of personality changes with Aβ1-42, but we did not find any association with the tau 
and ptau-181 levels. While the tau/Aβ1-42 and ptau-181/Aβ1-42 ratios may be considered as markers of 
concomitant cerebral AD pathology (amyloid pathology and tau-related neurodegeneration), their asso-
ciations with personality changes seem to be largely due to associations with the Aβ1-42 concentrations. 
The lack of associations with tau and ptau181 levels in the multivariate models does not exclude rela-
tionships with personality changes. In particular, our observation of correlations between both tau and 
ptau-181 levels and changes in neuroticism diserves investigation in future studies. Regarding the robust 
associations of personality changes with Aβ1-42, we can only speculate about their underlying mecha-
nisms. One possible explanation is that personality changes may start very early in the clinical course of 
AD, along with very subtle cognitive changes that have been recently described to be associated with 
amyloid pathology (Petersen et al., 2016), while changes in tau and ptau-181 concentrations are still 
ongoing and, hence, at an intermediate level (Jack Jr et al., 2013). Interestingly, a recent study found 
associations between cerebral amyloid pathology as measured by Pittsburgh compound B (PiB)-PET im-
aging and cognitive complaints in cognitively unimpaired subjects with high neuroticism (Snitz et al., 
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2015) while another study in subjects with MCI reported an association between amyloid pathology and 
anxiety (Bensamoun et al., 2015). In our study, anxiety score did not differ between CI and control 
groups but was lower in the AD CSF group as compared to the non-AD CSF participants. This last finding 
might have emerged from the fact that the group with a non-AD CSF profile included both CI and control 
subjects. Depression and anxiety symptoms may in part explain cognitive impairment in this group, and 
their relative contribution may be higher as compared to the group of participants with an AD CSF pro-
file.There may be different explanations for the observed personality changes in patients developing 
cognitive impairment and dementia. Some researchers emphasize the role of premorbid personality in 
modulating the risk of cognitive impairment in later life. For example, a study  showed an association 
between higher levels of premorbid conscientiousness and reduction in MCI and AD incidence, as well as 
with reduced cognitive decline (Wilson et al., 2007). In a longitudinal study in subjects confirmed post-
mortem to have AD neuropathology, greater scores on conscientiousness and lower scores on neuroti-
cism were associated with a reduced risk or delay to develop clinical dementia (Terracciano et al., 2013). 
Thus, lower conscientiousness may represent an increased vulnerability, while lower neuroticism sug-
gests an increased resilience of developing clinical dementia, even among people with AD neuropatholo-
gy. Premorbid personality may thus be acting as a determinant factor so that the original personality 
changes as AD advances (Welleford et al., 1995). Furthermore, lower consciousness and higher neuroti-
cism is also associated with greater vulnerability to metabolic syndrome (Sutin et al., 2010a), inflamma-
tory risk profile (Sutin et al., 2010b), smaller volume of medio-temporal and prefrontal regions and 
greater decline in volume with advancing age (Jackson et al., 2011), and with severity of white matter 
lesions in MCI patients (Duron et al., 2014). While premorbid personality characteristics may influence 
the risk of developing cerebral pathology and related cognitive impairment, changes in personality may 
represent the adaptive reaction to the individual’s experience of cognitive and functional impairment or 
may be more directly related to developing cerebral pathology, or both. Our findings show for the first 
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time that specific changes in personality domains, more precisely, increasing neuroticism and decreasing 
extraversion and conscientiousness are predicted not only by severity of cognitive impairment, but also 
by cerebral amyoid pathology as measured by the CSF Aβ1-42. 
Concerning the APOEε4 factor, one previous study showed that the carriers of APOEε4 with high scores 
on neuroticism and extraversion had poorer cognitive functioning and higher incidence of AD compared 
to APOEε4 carriers with lower neuroticism and extraversion scores (Dar-Nimrod et al. (2012). 
Terracciano et al. (2014) found that including APOE ε4 allele as an additional covariate did not moderate 
the association between personality and increased AD incident. In our study, APOEε4 status, as ex-
pected, differed significantly across clinical and control groups, but was not associated with changes in 
personality domains. 
 The main strengths of our study are the usage of validated instruments, the comprehensive personality 
and clinical assessment and the inclusion of factors with established effects on the relationship between 
cerebral pathology and clinical manifestations. One limitation is that the personality traits were not as-
sessed objectively, since the questionnaire to assess personality characteristics was filled by the subjects’ 
proxies. In addition, evaluating subjects’ premorbid personality retrospectively does not necessarily pro-
vide reliable descriptions, as it may be influenced by the impact of the cognitive decline on the personal 
relationship between caregiver and patient. Although personality description made by participants’ rela-
tives may be considered as subjective and not reliable, this approach corresponds to clinical practice 
when investigating cognitive decline in single patients. Some of the predictive biomarkers effect on per-
sonality change faded when taking into account age, gender, cognitive status, and APOEε4 status as co-
variate variables. The reason for this might be that the regression models controlled for many variables, 
and the sample size might not be large enough to detect the effects of biomarkers on the changes of 
some personality domains. While the comprehensive personality assessment by the NEO-PI-R may be 
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too time consuming to be used in clinical practice, short instruments focussing on specific personality 
changes, notably in domains of neuroticism, extraversion and conscientiousness, may be considered 
when examining elderly patients with cognitive decline. 
5. Conclusions
Subjects with cognitive decline undergo early and specific personality changes as compared to healthy 
controls. There is an association between cerebral AD pathology, as measured by CSF biomarkers and 
specific changes in personality characteristics, in particular in neuroticism, extraversion and conscien-
tiousness. Our findings suggest that in elderly subjects there is a specific pattern of personality changes 
related to cerebral amyloid and tau pathology. Likely to be more than a behavioural and emotional reac-
tion to cognitive decline, personality changes may represent the manifestation of AD pathology at early 
clinical disease stages. Further studies with larger sample are needed in order to confirm these findings 
and their potential clinical implications, and to better understand the nature of personality changes in 
relation to brain pathology.
6. Declarations
6.1 List of abbreviations 
Aβ1-42 Amyloid-β1-42 
AD Alzheimer’s disease 
ADL Activities of daily living 
APOEε4 ε4 allele of the Apolipoprotein E 
CDR Clinical Dementia Rating Scale 
CI Cognitive Impairment 
CSF Cerebrospinal fluid 
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DSM Diagnostic and Statistical Manual of Mental Disorders 
FFM Five-Factor Model 
HAD Hospital Anxiety and Depression Scale 
IQCODE Informant Questionnaire on Cognitive Decline in the Elderly 
MMSE Mini-Mental State Examination 
ml Millilitre 
NEO-PI-R Revised NEO Personality Inventory 
NPI Neuropsychiatric Inventory 
ptau-181 Phosphorylated tau 
SD Standard deviation 
tau total-tau 
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8. Figures titles and legends  504 
Figure 1 Differences in anxiety, MMSE, change in neuroticism, and change in conscientiousness scores 505 
between non-pathological and pathological CSF biomarker level groups. 506 
ChangeN, change in neuroticism; ChangeC, change in conscientiousness; MMSE, Mini Mental State Ex-507 
amination; NP CSF, non-pathological CSF biomarkers level group; P CSF, pathological CSF biomarkers 508 
level group. 509 
Table 1 Demographics and descriptive statistics 
  
Controls CI Statistical 
test 
P 
n = 44 n = 66 
Gender  
Males N=14 (31.8%) N=30 (45.5%) 
chi 0.155 
Females N=30 (68.2%) N=36 (54.5%) 
Age 
Mean 66 74 
t <0.001 
SD 6.57 6.54 
Education level  
≤ 9 years N=3   (6.8%) N=11 (16.7%) 
chi 0.113 10-12 years N=22 (50.0%) N=34 (51.5%) 
> 12 years N=19 (43.2%) N=21 (31.8%) 
MMSE 
Mean 28.5 26.0 
t <0.001 
SD 1.42 3.36 
HAD Depression score 
Mean 3.79 4.18 
t 0.55 
SD 3.56 3.06 
HAD Anxiety score 
Mean 6.79 6.45 
t 0.65 
SD 4.24 3.2 
QPC score  
Mean 1.56 2.54 
t <0.01 
SD 1.5 1.89 
IQCODE score 
Mean 3.067 3.467 
t <0.001 
SD 0.42 0.54 
APOEε4 carriers 
no  36 (81.8%) 36 (54.5%) 
chi <0.01 
yes    8 (18.2%) 29 (43.9%) 
Aβ1-42 pg/ml 
Median 1053 668.75 
U <0.001 
IQR 289.6 357.8 
tau pg/ml 
Median 209.3 394.35 
U <0.001 
IQR 115.4 361.3 
ptau-181 pg/ml 
Median 46.5 62.3 
U <0.001 
IQR 25.2 44.5 
tau/Aβ1-42 pg/ml 
Median 0.219 0.554 
U <0.001 
IQR 0.115 0.765 
ptau-181/Aβ1-42 pg/ml 
Median 0.047 0.101 
U <0.001 
IQR 0.02 0.097 
CI, Cognitive impairment; MMSE, Mini Mental State Examination; HAD, Hospital Anxiety and Depression Scale; 
APOEε4, epsilon 4 allele of the Apolipoprotein E; QPC, cognitive complaints questionnaire; IQCODE, Informant 
Questionnaire on Cognitive Decline in the Elderly; IQR, Interquartile range; U, Mann-Whitney U statistics. 
Table 2 Personality changes between groups 
  Controls (N=44) CI (N=66) 
    
Personality  
Mean (SD) Mean (SD) U P 
domains 
RetroN 83.52 (22.94) 79.27 (21.26) 1303 0.363 
RetroE 105.32 (15.99) 100.68 (22.68) 1290 0.324 
RetroO 107.59 (17.27) 94.45 (17.22) 801 < 0.001 
RetroA 128.82 (16.46) 127.76 (19.15) 1420 0.845 
RetroC 128.16 (20.40) 123.89 (19.70) 1295 0.338 
CurrentN 83.95 (22.78) 88.38 (23.47) 1326 0.442 
CurrentE 103.02 (18.35) 92.85 (24.59) 1058  < 0.05 
CurrentO 106.75 (18.82) 92.76 (18.09) 810 < 0.001 
CurrentA 128.70 (15.55) 125.68 (19.79) 1282 0.299 
CurrentC 127.66 (19.97) 109.98 (22.90) 859 < 0.001 
ChangeN   0.43 (10.01)    9.11 (13.00) 710 < 0.001 
ChangeE -2.30 (7.26)   -7.83 (11.86) 888 < 0.001 
ChangeO -0.84 (5.69)   -1.70 (4.26) 1279 0.396 
ChangeA -0.11 (2.31)   -2.08 (6.44) 1059  < 0.05 
ChangeC -0.50 (4.50) -13.91 (19.63) 647 < 0.001 
ChangeN, change in Neuroticism; ChangeE, change in Extraversion; ChangeO, change in openness to experience; 
ChangeA, change in agreeableness; ChangeC, change in conscientiousness; SD, Standart Deviation; Controls, 
Healthy Controls; CI, cognitive impairment; U, Mann-Whitney U statistics. 
Table 3 Non-pathological and pathological CSF biomarkers levels groups comparison 
 
Non-AD  CSF 
(N=66) 
AD CSF           
(N = 44) p 
Depression score     4.21     3.64     0.369 
Anxiety score     7.16     5.69 < 0.05 
MMSE score 27.9 25.8 < 0.01 
Personality changes 
   Neuroticism     2.9     8.8 < 0.05 
Extraversion    -3.6    -6.8     0.081 
Openness    -0.6    -1.9 0.158 
Agreeableness    -0.9    -1.6 0.536 
Conscientiousness    -4.6   -12.7 < 0.05 
MMSE, Mini Mental State Examination; non-AD CSF, non-pathological CSF biomarkers level group; AD 
CSF, pathological CSF biomarkers level group. 
Table 4a Model estimates in linear and robust regressions 
  Linear regression Robust regression 
   β t Adj. R
2
 F β t F 
Change N MMSE -0.822* -1.986 
0.12 6.36*** 
-0.793*** -3.831 
12.17***   Aβ1-42 -0.011* -2.303 -0.005* -2.073 
  tau   0.001   0.487   0.002   1.081 
Change E MMSE   0.577   1.676 
0.14 7.24*** 
  0.735***   3.611 
12.99***   Aβ1-42   0.011*   2.599   0.008***   3.502 
  tau -0.003 -0.857   0.001   0.468 
Change O MMSE   0.157   0.946 
0.05 3.14* 
  0.117   1.562 
 3.02   Aβ1-42   0.003   1.812   0.001   1.744 
  tau   0.001 -0.592   0.000 -0.215 
Change A MMSE   0.047*   2.622 
0.04 2.76* 
  0.287***   4.301 
 8.15***   Aβ1-42 -0.000 -0.12   0.000   1.022 
  tau -0.000 -0.064   0.000   0.058 
Change C MMSE   2.375***   4.807 
0.30 16.58*** 
  2.016***   5.720 
19.51***   Aβ1-42   0.012*   2.145   0.009*   2.268 
  tau -0.002 -0.632 -0.003 -1.063 
ChangeN, change in Neuroticism; ChangeE, Change in Extraversion; ChangeO, change in Openness to Experience; 
ChangeA, change in Agreeableness; ChangeC, change in Conscientiousness; MMSE, Mini Mental State Examination. 
β,unstandartised regression coefficient. 
* p < .05 ; ** p < .01 ; *** p < .001 . 
Table 4b Model estimates in linear and robust regressions 
  Linear regression Robust regression 
   β t Adj. R
2
 F β t F 
Change N MMSE -0.909* -2.129 
0.13 6.42*** 
-0.889*** -4.574 
14.69***   Aβ1-42 -0.013** -2.684 -0.006** -2.766 
  ptau -0.009 -0.297 -0.011 -0.764 
Change E MMSE   0.634   1.776 
0.14 6.90*** 
  0.783***   3.761 
13.48***   Aβ1-42   0.012**   3.012   0.009***   3.686 
  ptau -0.000 -0.024   0.012   0.753 
Change O MMSE   0.167   0.968 
0.05 2.97* 
  0.137   1.696 
 2.99*   Aβ1-42   0.004*   2.054   0.002   1.874 
  ptau -0.002 -0.182   0.001   0.243 
Change A MMSE   0.497**   2.658 
0.05 2.75* 
  0.302***   4.553 
8.44***   Aβ1-42 -0.000 -0.036   0.001   1.073 
  ptau   0.005   0.386   0.003   0.587 
Change C MMSE   2.556***   5.012 
0.30 16.42*** 
  2.208***   6.071 
19.33***   Aβ1-42   0.015**   2.629   0.011**   2.716 
  ptau   0.031   0.805   0.047   1.725 
ChangeN, change in Neuroticism; ChangeE, Change in Extraversion; ChangeO, change in Openness to Experience; 
ChangeA, change in Agreeableness; ChangeC, change in Conscientiousness; MMSE, Mini Mental State Examination. 
β,unstandartised regression coefficient. 
* p < .05 ; ** p < .01 ; *** p < .001 . 
Table 5 Spearman's correlations between CSF biomarkers and personality changes, retrospective, and 
current personality assessments (N=110) 
Personality 
domains 
Aβ1-42 tau ptau-181 tau/Aβ1-42 
ptau-181/ 
Aβ1-42 









-0.15   
RetroO 0.15 
 









-0.01   
RetroC -0.10   -0.03   -0.04   0.03   0.04   
CurrentN -0.03   0.14   0.07   0.13   0.07   
CurrentE 0.16 
 
-0.23 * -0.16 
 
-0.27 ** -0.24 * 









-0.08   
CurrentC 0.18   -0.18   -0.16   -0.21 * -0.21 * 
ChangeN -0.36 *** 0.39 *** 0.32 ** 0.46 *** 0.41 *** 
ChangeE 0.38 *** -0.10   -0.05   -0.21 * -0.21 * 
ChangeO 0.17   -0.13   -0.13   -0.17   -0.20 * 
ChangeA 0.20 * -0.20 * -0.18   -0.22 * -0.21 * 
ChangeC 0.34 *** -0.22 * -0.18   -0.32 ** -0.31 ** 
 
Retro, retrospective personality assessment; Current, current personality assessment; Change, personality change; 





Instructions to proxy ratters (translated from French) 
Read carefully these instructions before beginning. Below indicate the profession, age, gender, and 
education level of the person that you are about to evaluate. This questionnaire contains 240 
statements. Read carefully each of them. For each statement choose the answer that describes your 
proxy the best 5 years before the beginning of the first symptoms, then choose the answer that 
describes your proxy the best at this moment. 
There are no “good” or “bad” answers and you do not need to have a special expertise to fill this 
questionnaire.  The goal of this questionnaire will be reached if you describe the person and you express 
your opinion as accurately as possible. Please answer every question. If you happen to make a mistake or 
if you change your opinion, do not erase your answer. Note an “X” on the wrong answer and surround 
the correct answer.  
 
